ArticleFrontiers in cellular and infection microbiology2026
Antimicrobial resistance phenotypes, disinfectant susceptibility, and resistance-associated gene detection in carbapenem-resistant Pseudomonas aeruginosa from two tertiary hospitals in Urumqi, China.
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To characterise antimicrobial resistance phenotypes, Methods: Eighty nonduplicate CRPA isolates were consecutively recovered from clinical specimens at two tertiary hospitals in Urumqi between January 2025 and March 2026. Antimicrobial susceptibility was determined using the VITEK 2 system, with disk diffusion performed when confirmatory testing was required, and interpreted according to CLSI M100-S31 (2021). Carbapenemase production was assessed by the modified carbapenem inactivation method (mCIM). A broth microdilution assay adapted from antimicrobial susceptibility testing, and not a standardised biocide efficacy test, was used to compare minimum inhibitory concentrations (MICs) and minimum bactericidal concentrations (MBCs) of benzalkonium bromide, ethanol, povidone-iodine, and a chlorine-containing disinfectant between isolate groups. Polymerase chain reaction (PCR) was performed to detect carbapenem resistance-associated genes Results: Of the 80 CRPA isolates, 24 (30.00%) were extensively drug-resistant (XDR) and 56 (70.00%) were non-XDR. Resistance rates to imipenem and meropenem were 83.70% and 68.70% respectively, and no isolate was susceptible to either agent. Overall resistance rates to aztreonam, piperacillin/tazobactam, levofloxacin, ceftazidime, cefepime, amikacin, and tobramycin were 37.50%, 30.00%, 26.30%, 25.00%, 21.30%, 12.50%, and 6.30% respectively. The expected oprD amplicon failed to amplify in 55 isolates (68.75%). mCIM was positive in 23 isolates (28.75%), with 95.0% agreement with PCR-detected carbapenemase gene carriage (Cohen's κ 0.871, 95% CI 0.748-0.994). Detection rates for Conclusions: CRPA isolates from these two hospitals showed uniform nonsusceptibility to carbapenems, with failure to amplify the expected oprD target the most frequent molecular observation. XDR isolates showed higher benzalkonium bromide MICs
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.